Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MannKind Corp. (NASDAQ: MNKD).

Full DD Report for MNKD

You must become a subscriber to view this report.


Recent News from (NASDAQ: MNKD)

The FDA Clinical Hold On Zafgen's Diabetes Drug May Be A Blessing
On June 2014, Zafgen ( ZFGN ) introduced its initial public offering as... ...a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity. Beloranib, our lead product candidate, is a novel, first-in-class, for the treatment ...
Source: SeekingAlpha
Date: November, 30 2018 09:35
MannKind: Where Is This Company Headed?
MannKind ( MNKD ) investors were expecting a lot on the conference call, and perhaps got a bit of a dose of reality. The company reported Afrezza net revenue of $4.4 million for Q3 and did not really address its guidance on the call. Simply stated, it is widely apparent that the company will m...
Source: SeekingAlpha
Date: November, 06 2018 16:02
MannKind Quarterly Call Hits And Misses
MannKind ( MNKD ) reported its Q3 2018 numbers on November 1st at 9:00 AM. The company reported a loss, which was expected, and the call was actually a pretty straightforward event. There are a few key takeaways that I saw during the call that I would like to address before getting into th...
Source: SeekingAlpha
Date: November, 02 2018 02:50
MannKind Corporation (MNKD) CEO Michael Castagna on Q3 2018 Results - Earnings Call Transcript
MannKind Corporation (MNKD) Q3 2018 Earnings Conference Call November 1, 2018 9:00 a.m. ET Executives Rose Alinaya - IR Michael Castagna - CEO Steven Binder - CFO Pat McCauley - CCO David Kendall - CMO Analysts Brooks O'Neil - Lake Street Capital Markets Oren Livnat -...
Source: SeekingAlpha
Date: November, 01 2018 14:26
MannKind Q3 revenues up 125%; shares down 1% premarket
MannKind ( MNKD ) Q3 results: Revenues: $4.5M (+125.0%); Commercial product sales: $4.4M; Collaborations revenue: $0.08M (+33.3%). More news on: MannKind Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 09:02
MannKind beats by $0.02, misses on revenue
MannKind (NASDAQ: MNKD ): Q3 GAAP EPS of -$0.16 beats by $0.02 . More news on: MannKind Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 08:06
MannKind Corporation Reports 2018 Third Quarter Financial Results
Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus royalties Executed research agreement for a second Technosphere formulation with United Therapeutics for ...
Source: GlobeNewswire
Date: November, 01 2018 08:00
MannKind: Scripts, Cash, And Quarterly Calls
MannKind (MNKD) investors are in for an interesting week. Afrezza scripts came in essentially flat for the week ending October 19th, and we should see a cash infusion of $45 million relating to the United Therapeutics (UTHR) deal. On top of that, United Therapeutics is scheduled to have a qua...
Source: SeekingAlpha
Date: October, 30 2018 06:04
MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018
WESTLAKE VILLAGE, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results and other corporate developments at 9:00 AM (Eastern Time) on Thursday, November 1, 2018. Pre...
Source: GlobeNewswire
Date: October, 25 2018 17:00
Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cato Corporation (NYSE:CATO), Roadrunner Transportation Systems, Inc (NYS...
Source: GlobeNewswire
Date: October, 24 2018 07:20

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-121.741.78011.801.741,351,942
2018-12-111.721.731.771.691,418,220
2018-12-101.731.701.791.681,694,813
2018-12-071.741.7451.841.712,282,409
2018-12-061.721.7151.741.671,093,774

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12176,642366,38848.2117Short
2018-12-11243,402447,24054.4231Short
2018-12-10310,807538,96057.6679Short
2018-12-07399,212641,45462.2355Short
2018-12-06222,200371,30559.8430Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MNKD.


About MannKind Corp. (NASDAQ: MNKD)

Logo for MannKind Corp. (NASDAQ: MNKD)

Not available

 

Contact Information

 

 

Current Management

  • Juergen A. Martens / COO
  • Richard A. Anderson / CFO
  • Alfred A. Mann / Chairman
  • Ronald Consiglio /
  • Michael Friedman /
  • Kent Kresa /
  • David H. MacCallum /
  • Henry L. Nordhoff /
  • James S. Shannon /

Current Share Structure

  • Market Cap: $222,864,203 - 05/11/2018
  • Issue and Outstanding: 120,467,137 - 02/09/2018

 


Recent Filings from (NASDAQ: MNKD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 17 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 06 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: April, 06 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 29 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (NASDAQ: MNKD)

Daily Technical Chart for (NASDAQ: MNKD)


Stay tuned for daily updates and more on (NASDAQ: MNKD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MNKD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MNKD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MNKD and does not buy, sell, or trade any shares of MNKD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/